



**LUPIN**

March 29, 2017

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards launch of Abacavir and Lamivudine tablets, 600 mg/300 mg for which the Company received USFDA approval. It is the AB rated generic equivalent of ViiV Healthcare Company's Epzicom® tablets, 600 mg/300 mg which is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**



For **R. V. SATAM**  
**COMPANY SECRETARY**

Encl.: a.a.

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

## **Lupin launches Generic Epzicom® tablets in the US**

**Mumbai, Baltimore, March 29, 2017:** Pharma Major Lupin Limited (Lupin) announced today the launch of Abacavir and Lamivudine tablets, 600 mg/300 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Abacavir and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company's Epzicom® tablets, 600 mg/300 mg. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Epzicom® tablets had US sales of USD 388.1 million (IMS MAT December 2016).

### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5<sup>th</sup> and the 6<sup>th</sup> largest generics pharmaceutical company by market capitalization (December 31<sup>st</sup>, 2016, Bloomberg) and sales globally (September 30<sup>th</sup>, 2016, Bloomberg). The Company is the 5<sup>th</sup> largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 2<sup>nd</sup> largest Indian pharmaceutical company by revenues; the 6<sup>th</sup> largest generic pharmaceutical player in Japan and the 4<sup>th</sup> largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31st March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

**For further information or queries please contact –**

Arvind Bothra  
Head – Investor Relations and M&A  
Ph: +91-22-66402137  
Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

*\*Safe Harbor Statement*

*Epzicom® is the registered trademark of ViiV Healthcare Company.*